title: TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.
abstract: Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein which is associated with tumor development and progression in a variety of epithelial carcinomas, while its expression and role in gliomas have not been considered. The aim of the study was to investigate TROP2 expression in malignant gliomas with different World Health Organization (WHO) classification and its correlation with tumor proliferation and angiogenesis. Immuohistochemistry was used to determine TROP2 and Ki-67 expression and microvessel density (MVD) in tumor specimens and normal brain tissues from 69 glioma patients and the relationship between TROP2 and Ki-67 and MVD was investigated. Immunohistochemistry results showed that the TROP2 expression was found in 59 (85.5 %) of the 69 tumor specimens, but no expression in normal brain tissues. Furthermore, TROP2 expression is significantly higher in WHO grade III (P = 0.025) and WHO grade IV (P = 0.011) gliomas than in WHO grade II gliomas. TROP2 expression correlates with Ki-67 (r = 0.676, P = 0.012) and MVD (r = 0.365, P = 0.035), but not with gender or age in human gliomas. These results suggested that the TROP2 correlated with malignancy, proliferation and angiogenesis in human gliomas. This is the first study describing TROP2 expression in gliomas and its proliferation and angiogenesis-related characteristic may serve as a potential therapeutic target for glioma treatment.
authors: School of Medicine, Shandong University, Jinan, People's Republic of China.
authors: Shanglei
authors: S
authors: Ning
authors: Nan
authors: N
authors: Liang
authors: Bin
authors: B
authors: Liu
authors: Xin
authors: X
authors: Chen
authors: Qi
authors: Q
authors: Pang
authors: Tao
authors: T
authors: Xin
mesh_terms: D000328:Adult; D000367:Age Factors; D018952:Antigens, CD34 / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000378:metabolism*; D001932:Brain Neoplasms / Q000150:complications* / Q000235:genetics / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000235:genetics* / Q000378:metabolism*; D049109:Cell Proliferation; D015972:Gene Expression Regulation, Neoplastic; D005910:Glioma / Q000150:complications* / Q000235:genetics / Q000473:pathology; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000209:etiology* / Q000235:genetics*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012737:Sex Factors; D018709:Statistics, Nonparametric
chemical_list: D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; D019394:Ki-67 Antigen; C499380:TACSTD2 protein, human
references: Clin Med Insights Oncol. 2011;5:117-29
references: 21603247
references: Mol Cancer Ther. 2008 Feb;7(2):280-5
references: 18281513
references: Biochim Biophys Acta. 2009 Dec;1796(2):309-14
references: 19683559
references: J Neurooncol. 2009 May;93(1):79-87
references: 19430884
references: Cancer Treat Res. 2004;117:263-84
references: 15015565
references: Nat Immunol. 2011 Jul 19;12(8):715-23
references: 21772280
references: Genes Dev. 2012 Oct 15;26(20):2271-85
references: 23070813
references: Pathol Oncol Res. 2001;7(4):267-78
references: 11882906
references: Nat Med. 2003 Jun;9(6):669-76
references: 12778165
references: Mol Cancer. 2010 Sep 21;9:253
references: 20858281
references: Hematol Oncol Clin North Am. 2004 Oct;18(5):1007-21, viii
references: 15474332
references: Cancer Res. 2008 Oct 1;68(19):8113-21
references: 18829570
references: Med Oncol. 2011 Dec;28(4):1012-6
references: 20571936
references: J Clin Pathol. 2009 Feb;62(2):152-8
references: 18930986
references: Cancer. 2006 Jul 1;107(1):162-70
references: 16721804
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: Clin Cancer Res. 2011 May 15;17(10):3157-69
references: 21372224
references: Oncogene. 2013 Jan 10;32(2):222-33
references: 22349828
references: Mod Pathol. 2008 Feb;21(2):186-91
references: 18084248
references: Neuro Oncol. 2009 Feb;11(1):80-91
references: 18784279
references: Cancer. 2011 Jul 15;117(14):3163-72
references: 21246534
references: Clin Cancer Res. 2006 May 15;12(10):3057-63
references: 16707602
references: N Engl J Med. 2008 Oct 23;359(17):1850; author reply 1850
references: 18946076
references: J Signal Transduct. 2012;2012:483040
references: 22830012
references: Br J Cancer. 2008 Oct 21;99(8):1290-5
references: 18813308
references: Cancer. 1996 Jan 15;77(2):362-72
references: 8625246
references: J Neurooncol. 2012 May;107(3):559-64
references: 22183444
references: J Neurooncol. 2012 Feb;106(3):543-9
references: 21984063
references: Am J Pathol. 2003 Apr;162(4):1083-93
references: 12651601
references: Clin Cancer Res. 2004 Aug 15;10(16):5391-402
references: 15328177
references: J Exp Clin Cancer Res. 2011 Nov 10;30:106
references: 22075385
references: Proc Natl Acad Sci U S A. 1981 Aug;78(8):5147-50
references: 7029529
references: Pathol Oncol Res. 2006;12(3):143-7
references: 16998593
references: Mol Oncol. 2010 Oct;4(5):385-96
references: 20688584
references: Breast Cancer Res Treat. 2004 Mar;84(2):173-82
references: 14999147